Background: Acute Myocardial Infarction (AMI) as cardiovascular disease is a significant cause of death worldwide and requires examining cardiac biomarkers such as Troponin T (TnT) for diagnosis. However, increased troponin levels are often found in non-AMI patients. Soluble Suppression of Tumorigenicity 2 (sST2) as a novel biomarker has known will increase after the occurrence of AMI. This study aims to evaluate the relationship of sST2 and TnT levels in AMI patients at Sanglah General Hospital, Bali, Indonesia

Methods: The study was conducted among 61 participants during August-December 2020 by consecutive sampling. The samples were examined for TnT levels using a Roche Cobass h232 and sST2 with the Human sST2 Elabscience© Enzyme-linked Immunosorbent Assay (ELISA) Kit. Normality and correlation tests were performed between the two parameters. Data were analyzed using SPSS version 17 for Windows.

Results: The average age of participants was 59.5±10.0 years old. Most of the participants were male and had hypertension history in STEMI (71.0% and 67.7%) and NSTEMI (70.0% and 79.0%) groups. There is no significant difference in BMI between STEMI (23.5±3.1 kg/m²) and NSTEMI (24.6±3.8 kg/m²) (p=0.319). However, there was a significant moderate positive correlation between TnT and sST2 levels (r=0.394, p=0.002).

Conclusion: There was an increase in troponin T and sST2 levels in AMI patients at Sanglah Hospital. There is a significant positive correlation between sST2 levels and troponin T levels in AMI patients at Sanglah Hospital.